Dr. Norman E. (Ned) Sharpless, director of the National Cancer Institute, will serve as acting commissioner of the Food and Drug Administration, Alex M. Azar III, secretary of health and human services, announced on Tuesday. Dr. Sharpless temporarily will fill the post being vacated by Dr. Scott Gottlieb, who stunned public health experts, lawmakers…
Executive Summary Genentech/AbbVie drug becomes the seventh product known to be pilot-testing US FDA’s new pathway; our infographic details the program’s goals and how it has been used so far for more efficient reviews of supplemental oncology indications. Genentech Inc. is at the forefront of sponsors vying to use the US FDA Oncology Center…
The US Department of Health and Human Services (HHS) announced Tuesday that Dr. Ned Sharpless, current director of the National Cancer Institute (NCI) at the National Institutes of Health, will serve as acting US Food and Drug Administration (FDA) commissioner when Scott Gottlieb steps down next month. Sharpless, who has served as NCI director…
National Cancer Institute Director Norman “Ned” Sharpless will become acting commissioner of the Food and Drug Administration, Health and Human Services Secretary Alex Azar said Tuesday. Sharpless, 52, an accomplished researcher, oncologist and administrator, has been director of the cancer institute for about 18 months, earning good reviews from cancer advocates, patient groups and…
Executive Summary Norman Sharpless, director of the National Cancer Institute, will become acting FDA commissioner when Scott Gottlieb departs. The US FDA’s incoming acting commissioner shares an enthusiasm for clinical trial system reform that should mesh well with the message many senior agency officials have been pushing for years. National Cancer Institute Director…
National Cancer Institute Director Ned Sharpless will become acting commissioner of FDA when current Commissioner Scott Gottlieb resigns in early April, HHS Secretary Alex Azar announced at a House hearing Tuesday (March 12). Sharpless was among three candidates viewed as top contenders for the job, and Azar said Sharpless’ “deep scientific background and expertise…
It’s official: NCI Director Ned Sharpless will take on the role of acting commissioner of the FDA. But what does the appointment mean for interagency cooperation between the federal government’s main medical research and innovation arm and its industry regulator? Outgoing FDA Commissioner Scott Gottlieb, who is expected to step down in early April,…
Norman E. “Ned” Sharpless, the current head of the National Cancer Institute at the National Institutes of Health, will serve as the acting Food and Drug Administration Commissioner when Scott Gottlieb steps down in April, Health and Human Services Secretary Alex Azar told lawmakers Tuesday. The administration is still considering who to nominate as…
U.S. President Donald Trump’s administration has tapped National Cancer Institute Director Norman Sharpless to serve as acting commissioner for the Food and Drug Administration, following the resignation of Scott Gottlieb earlier this month. Sharpless, who has led the National Institutes of Health’s cancer unit since 2017, will take over following Gottlieb’s exit in April, the…
On 11 March, US President Donald Trump released his budget proposal for the 2020 fiscal year, which begins on 1 October 2019. Nature’s news team reports on what Trump’s budget would mean for US government science agencies. National Institutes of Health The White House plan would give the National Institutes of Health (NIH) US$34.4…
